Company Overview and News
Largest lender in Europe and Hong Kong to push facial recognition while Citi focuses on voice, as major players embrace latest fintech
Big players in Hong Kong such as such as HSBC, Hang Seng Bank and Standard Chartered are just scratching the surface when it comes to the use of artificial intelligence
It may be the era of disruptive technologies, but few industry sectors have experienced an impact as far-reaching as that of fintech on the finance sector. A growing number of leading fintech companies are based in Hong Kong, and the city has positioned itself as Asia’s premier fintech hub for start-ups, accelerators, incubators and investors. It is vital for Hong Kong to develop its own pool of talent to drive the industry forward, and this will open the way for a diverse range of new career opportunities.
HSBC has spent US$2.3 billion on enhancing its digital capabilities globally. Between 2015 and 2017, the bank created new platforms and partnered with technology companies such as Tencent’s popular messaging application WeChat to serve its clients, Vivek Ramachandran, head of growth and innovation for HSBC global commercial banking, said in an interview with the South China Morning Post.
The move comes as the number of fixed-rate home loans being approved increases as buyers seek safety from further Fed rate increases
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
The money, from a group of banks including HSBC, is the first green loan in the city, which is aiming to turn itself into a regional hub for such financing
The Hong Kong government and HKEX should make gender pay gap reports compulsory as figures published by HSBC and Standard Chartered in the UK show there is an imbalance that needs to be corrected
“We’re now poised for growth,” said Standard Chartered group chief executive Bill Winters during a call with analysts last Tuesday, after the bank announced a rise in profits for 2017.
Hong Kong Financial Secretary Paul Chan delivers the annual budget at the Legislative Council in Hong Kong February 28, 2018. — Reuters picHONG KONG, Feb 28 — Hong Kong rolled out tax cuts, relief measures and capital spending in an expansionary budget today, after the city racked up a hefty budget surplus, targeting investments in high-technology industries to help raise its competitiveness.
Total number of companies on site up a third to 164,000, including 289 start-ups, half of which hail from Hong Kong
Hong Kong lags behind when it comes to embracing gender diversity in top leadership roles at major companies
CEO Louisa Cheang Wai-wan wants to develop new services to attract new generation of tech-savvy consumers
The following slide deck was published by Hang Seng Bank Ltd. ADR in conjunction with their 2017 Q4 earnings call.
Higher interest income and fee income from stockbroking and fund sales as well as lower bad debts contribute to the improved results
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...